how Fair Value spotted Centrus Energy’s 52% decline from overvaluation By Investing.com

Centrus Energy (LEU) has fallen 52% from $383 in October 2025 to $191.85 in April 2026 after JPM downgrade-related pressure, while InvestingPro’s Fair Value model still implies further downside with a $128 estimate versus the current price. Recent fundamentals weakened, with EBITDA down 40% to $53.3 million and EPS down 34% to $4.33, even as revenue slipped only modestly to $448.7 million. The article is primarily a valuation and analyst commentary piece, highlighting overvaluation, earnings deterioration, and dilution concerns from a planned $1 billion at-the-market offering.

Analysis

The key takeaway is not that the stock deserved to mean-revert; it is that the market was underwriting a step-function improvement in economics that has not yet shown up in cash generation. When a name rallies on policy optics, strategic partnerships, and narrative scarcity, the first-order risk is valuation; the second-order risk is dilution plus execution lag, which can compress per-share economics even if the business remains strategically important. That combination is especially toxic for a pre-scarcity industrial story because the marginal buyer is often momentum-driven rather than fundamental.

For competitors and adjacent beneficiaries, the real signal is that capital and attention may rotate away from single-name clean-energy exposure toward broader nuclear supply-chain exposure with better risk-adjusted setups. If enrichment capacity remains tight, the winners are likely to be the lower-multiple enablers and the less crowded uranium-cycle equities, not the headline name that already priced in years of optimism. The market is also implicitly telling us that government support is not the same as equity upside when capex intensity rises faster than incremental margin.

Near term, the main catalyst is not policy headlines but whether management can translate awards and partnerships into sustained EBITDA stabilization without issuing equity at depressed levels. If the next print shows another miss or dilution overhang persists, downside can remain asymmetric over the next 1-3 quarters because fundamental revisions and multiple compression tend to reinforce each other. The contrarian view is that the stock may already be closer to fair value on a purely mechanical basis, but it still screens expensive relative to the risk of recurring capital raises and slower-than-expected cash conversion.

Key Decisions for Investors

• Avoid initiating fresh long LEU here; if already owned, trim into any policy-driven spikes and treat rallies as exit liquidity over the next 1-2 quarters.
• Pair trade: short LEU against a basket of better-risked nuclear supply-chain beneficiaries (preferably lower-multiple uranium names) to isolate narrative premium compression over 3-6 months.
• If seeking exposure to the theme, rotate from LEU into PLTR/SMCI/APP-style momentum names only if the objective is growth momentum rather than industrial cash-flow exposure; otherwise stay out of LEU-specific risk.
• Consider buying short-dated put spreads on LEU into earnings or financing events, targeting a 1:2 to 1:3 risk/reward if dilution or another miss triggers a fresh de-rating.
• Set a re-entry trigger only after evidence of EBITDA stabilization and no additional equity issuance; until then, demand a meaningful discount to the current fair-value estimate before considering long exposure.